MedTrace Logo

EPI-STORM: Cytokine Storm in Organ Donors

NCT03786991 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2025-04-02

No results posted yet for this study

Summary

Kidney and liver transplantation are the treatment of choice and are often the last therapeutic option offered to patients with chronic renal and liver failure. More than 70% of kidneys and liver available for transplantation are obtained from donors following neurological death. Unfortunately, compared to living donation, transplant function, graft survival, and recipient survival are consistently inferior with kidneys and liver from neurologically deceased donors. This difference lies with the exacerbated pro-inflammatory state characteristic of deceased donors. Indeed, when neurologic death occurs, the immune system releases substances in the blood that could harm organs and particularly the liver and the kidneys. We believe that achieving a better understanding of the inflammatory processes of organ donors could be greatly informative to design future randomized controlled trial assessing the effect of personalized immunosuppressive therapy on organ donors to ultimately improve the care provided to donors so as to increase the number of organs available for transplantation and enhancing the survival of received grafts

Conditions

  • Organ Donation
  • Liver Transplantation
  • Kidney Transplantation
  • Graft Dysfunction

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Centre de recherche du CHUS

    collaborator UNKNOWN

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Dr Frédérick D'Aragon, MD FRCPC MSc · Université de Sherbrooke

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-16
Primary Completion
2025-03-24
Completion
2025-12-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786991 on ClinicalTrials.gov